Turkey Human Insulin Market size was valued at USD 135.59 million in 2023 and is anticipated to reach USD 169.44 million by 2032, at a CAGR of 2.48% during the forecast period (2023-2032).
The Turkey Human Insulin market is driven by several key factors, including the rising prevalence of diabetes, an aging population, and increased awareness of diabetes management. With the growing number of diabetic patients, there is an increasing demand for insulin, especially human insulin, which remains a preferred option due to its cost-effectiveness and reliability. Additionally, advancements in healthcare infrastructure, improvements in insulin delivery systems, and government support for diabetes care contribute to market growth. The shift towards affordable treatment options, coupled with greater access to healthcare services, is also bolstering demand. Furthermore, ongoing research and development initiatives aimed at improving insulin formulations and delivery methods are expected to shape the future of the market. The expanding focus on personalized healthcare and the increasing adoption of telemedicine and digital health solutions also plays a significant role in driving the market’s growth trajectory.
Geographically, the Turkey human insulin market is concentrated in major urban centers such as Istanbul, Ankara, and Izmir, where healthcare infrastructure is more advanced and the demand for insulin therapies is higher due to the larger diabetic populations. These cities benefit from better access to modern treatment options and insulin delivery devices. In rural regions, though the market size is smaller, increasing healthcare initiatives are driving awareness and insulin access. Key players in the Turkish human insulin market include multinational pharmaceutical companies such as Novo Nordisk, Eli Lilly, and Pfizer, along with local manufacturers like Atabay Enterprises. These companies play a crucial role in supplying insulin products and have a significant presence due to their strong distribution networks, innovative product portfolios, and collaborations with healthcare providers. Their continued investment in research, development, and market expansion is expected to shape the market dynamics in Turkey.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research!
The Turkey human insulin market was valued at USD 135.59 million in 2023 and is projected to reach USD 169.44 million by 2032, growing at a CAGR of 2.48%.
The global human insulin market was valued at USD 21,000 million in 2023 and is projected to reach USD 31,208 million by 2032, growing at a CAGR of 4.50% from 2023 to 2032.
Increasing diabetes prevalence in Turkey is a significant driver, with rising numbers of both Type 1 and Type 2 diabetes patients.
Technological advancements in insulin delivery systems, such as insulin pens and pumps, are reshaping diabetes management and boosting insulin demand.
Biosimilars and alternative diabetes treatments are posing competitive pressure on traditional human insulin products.
High reliance on imported insulin creates challenges in supply stability and pricing for the Turkish market.
Regional disparities exist, with major cities like Istanbul, Ankara, and Izmir accounting for the majority of market activity, while rural areas show gradual growth.
Leading players such as Novo Nordisk, Eli Lilly, and Atabay Enterprises dominate the market with strong distribution channels and ongoing innovations.
Report Scope
This report segments the Turkey Human Insulin Market as follows:
Market Drivers
Increasing Prevalence of Diabetes
The growing incidence of diabetes in Turkey is one of the primary drivers of the human insulin market. According to recent studies, the prevalence of diabetes in the country has steadily increased due to various factors, including unhealthy dietary habits, sedentary lifestyles, and an aging population. This increase in diabetes cases directly drives the demand for insulin, as it is a cornerstone of diabetes management. The rising number of people diagnosed with Type 1 and Type 2 diabetes creates a substantial and consistent need for insulin, making it a critical component of the healthcare system. The escalating health burden associated with diabetes highlights the need for effective treatment options, particularly human insulin, which remains a cost-effective and accessible therapy for managing blood sugar levels.
Government Initiatives and Healthcare Reforms
The Turkish government has introduced several healthcare reforms aimed at improving the accessibility and affordability of medical treatments, including insulin. These initiatives include the provision of subsidized healthcare, including insulin supplies, through the government’s social security system, which ensures that people, especially those with low-income levels, can access life-saving treatments. For instance, the World Health Organization (WHO) Health Systems Review outlines Turkey’s Health Transformation Program, which has significantly improved healthcare access and affordability. Moreover, Turkey has invested heavily in expanding healthcare infrastructure and improving the availability of medical products across the nation. Such efforts contribute to increased insulin availability, helping to meet the growing demand in both urban and rural regions. The government’s proactive stance on managing chronic diseases like diabetes and promoting public health further supports the steady growth of the human insulin market.
Advancements in Insulin Delivery Systems
Technological advancements in insulin delivery systems are significantly influencing the human insulin market in Turkey. The introduction of insulin pens, insulin pumps, and continuous glucose monitoring systems has revolutionized the way diabetes patients manage their condition. These innovations provide patients with more precise and convenient options for administering insulin, improving their overall quality of life. The growing adoption of these advanced delivery systems is increasing the demand for human insulin, as these devices typically require insulin formulations for effective usage. As more patients opt for these user-friendly systems, the market for human insulin is experiencing continued growth. Additionally, the development of improved insulin formulations that offer faster absorption rates and longer-lasting effects is also shaping the future of insulin therapy in Turkey.
Rising Awareness and Education on Diabetes Management
The increasing awareness and education surrounding diabetes management are further driving the demand for human insulin in Turkey. As public awareness of the risks and complications associated with poorly managed diabetes rises, more people are seeking medical advice and intervention to manage their condition effectively. For instance, the Globalization and Health Review discusses Turkey’s national diabetes awareness campaigns, which aim to improve early diagnosis and treatment adherence. Government campaigns, healthcare provider initiatives, and nonprofit organizations are playing a significant role in educating the population about diabetes prevention and treatment options. These efforts have encouraged early diagnosis and increased compliance with prescribed therapies, including insulin. As patients become more informed about the importance of insulin therapy in maintaining healthy blood glucose levels, the market for human insulin is expected to grow steadily. This trend is particularly important in Turkey, where healthcare access and patient education are improving across both urban and rural areas.
Market Trends
Surge in Diabetes Prevalence
The increasing prevalence of diabetes in Turkey is one of the primary drivers of the human insulin market. Turkey has witnessed a notable rise in the number of diabetes cases, particularly Type 2 diabetes, driven by changing lifestyles, unhealthy diets, physical inactivity, and an aging population. For instance, the Turkish Diabetes Epidemiology Study (TURDEP) found that the crude prevalence of diabetes in Turkey was 7.2%, with 2.3% previously undiagnosed cases. According to health reports, a significant portion of the Turkish population is either living with undiagnosed or uncontrolled diabetes, which is further contributing to the demand for insulin. As the number of diabetes cases continues to rise, the need for insulin, particularly human insulin, remains critical in managing the disease. Human insulin has long been a trusted, cost-effective, and widely used treatment option, making it the go-to therapy for many patients across the country. The increasing diabetes burden in Turkey is expected to continue fueling demand for insulin therapies, driving the growth of the market in the coming years.
Advancements in Insulin Delivery Technologies
Technological advancements in insulin delivery systems have been significantly shaping the human insulin market in Turkey. In recent years, there has been a marked shift toward more advanced insulin delivery methods, such as insulin pens, insulin pumps, and continuous glucose monitoring systems (CGM). For instance, the Insulin100 Report provides an overview of diabetes care advancements in Turkey, including the adoption of smart insulin pens and continuous glucose monitoring (CGM) systems. These devices have revolutionized diabetes management by offering greater convenience, precision, and improved patient outcomes. Insulin pens, in particular, have gained significant popularity due to their ease of use, portability, and accuracy in delivering the correct dosage of insulin. Furthermore, insulin pumps and CGM systems are helping patients achieve more stable blood glucose control, minimizing the risk of complications. As more Turkish patients embrace these advanced technologies, the demand for human insulin continues to rise, as these devices require consistent access to insulin to function effectively. The market is expected to benefit from the growing adoption of these innovative delivery systems in the long term.
Government Initiatives and Healthcare Investments
The Turkish government’s proactive initiatives to improve healthcare access and infrastructure have played an instrumental role in the growth of the human insulin market. Turkey has made significant strides in expanding its healthcare system, particularly for chronic disease management, including diabetes. With the introduction of the General Health Insurance (GHI) system and subsidized insulin prices, the government has ensured that insulin is more affordable and accessible to a broader segment of the population. These government-backed healthcare reforms are critical in facilitating insulin access for people from lower-income groups or those living in remote areas. Additionally, the Turkish government has invested in expanding public health programs aimed at raising awareness about diabetes prevention and management. This holistic approach ensures that more people are diagnosed and treated early, further fueling the demand for insulin therapies. The combination of these policies and healthcare reforms is expected to keep supporting the growth of the human insulin market in Turkey.
Shift Towards Insulin Analogues
A growing trend in the Turkish insulin market is the shift towards insulin analogues, which are gaining favor over traditional human insulin due to their improved pharmacokinetic properties. Insulin analogues are designed to mimic the natural pattern of insulin secretion in the body more effectively, leading to better control over blood sugar levels. These analogues offer a more predictable onset, peak, and duration of action, which helps in reducing the risk of hypoglycemia, a common issue with regular human insulin. As a result, insulin analogues are increasingly being prescribed by healthcare professionals in Turkey, especially for patients who require more precise blood glucose control or those who have difficulty managing their diabetes with standard human insulin. While human insulin remains the preferred and more affordable option for many, the growing awareness of the benefits of insulin analogues is gradually shifting the treatment landscape.
Market Challenges Analysis
High Dependency on Imports
One of the significant challenges facing the Turkey human insulin market is the high dependency on imports for insulin production. Although Turkey has a robust healthcare infrastructure, it lacks significant domestic manufacturing capacity for insulin, relying heavily on imports from multinational pharmaceutical companies. For instance, a sectoral analysis highlights that Turkey’s import dependency in manufacturing has increased significantly, particularly in pharmaceuticals. This dependency makes the market vulnerable to fluctuations in global supply chains, currency exchange rates, and international trade policies. The cost of imported insulin can fluctuate, and changes in global pricing can lead to affordability challenges for both patients and healthcare providers. Moreover, any disruption in the global supply chain, such as those caused by geopolitical tensions or pandemics, could lead to shortages, further exacerbating the problem of insulin accessibility and affordability in Turkey.
Competition from Biosimilars and Alternative Treatments
Another challenge facing the human insulin market in Turkey is the growing competition from biosimilars and alternative diabetes treatments. As the patents for many traditional insulin formulations expire, biosimilar insulin products have entered the market at more affordable prices, making them an attractive option for both patients and healthcare providers. Although biosimilars are not identical to human insulin, they are similar in composition and provide similar therapeutic effects. This shift towards biosimilars may reduce the demand for traditional human insulin products in the long term. Additionally, the increasing adoption of non-insulin-based diabetes treatments, such as oral medications and newer injectable drugs, could further challenge the market for human insulin. Patients seeking more convenient or effective alternatives may opt for these newer therapies, leading to reduced market share for human insulin.
Market Opportunities
The Turkey human insulin market presents significant opportunities driven by the increasing prevalence of diabetes and a growing demand for more effective and affordable treatment options. As the number of diabetes cases continues to rise, particularly in the aging population and among individuals with lifestyle-related risk factors, the need for insulin therapies becomes more pressing. With a large portion of the Turkish population still relying on traditional human insulin, there is a substantial opportunity for market expansion by improving access to insulin and enhancing patient education on diabetes management. Moreover, the government’s efforts to promote healthcare reforms, including subsidized insulin prices and better coverage through public health programs, create a favorable environment for market growth. Insulin manufacturers have the opportunity to cater to this growing demand by ensuring consistent supply and affordability, thus solidifying their market presence.
Additionally, technological advancements in insulin delivery systems and the increasing adoption of telemedicine offer new avenues for growth in the Turkish market. The rise of insulin pens, pumps, and continuous glucose monitoring devices presents opportunities for companies to enhance patient experience and improve treatment outcomes. As more diabetic patients opt for these advanced delivery methods, the demand for compatible insulin formulations will rise, providing further growth prospects. Furthermore, the shift toward personalized medicine and precision treatments offers a chance for human insulin manufacturers to collaborate with healthcare providers to develop tailored therapies for individual patients. Innovations in insulin formulation, such as the development of faster-acting or longer-lasting human insulin, can also meet evolving patient needs and improve market competitiveness. These trends create a dynamic and promising landscape for the continued expansion of the human insulin market in Turkey.
Market Segmentation Analysis:
By Device:
The Turkey human insulin market is segmented based on the type of delivery device, including insulin pens, syringes, and other methods. Among these, insulin pens have emerged as the most popular delivery device due to their convenience, ease of use, and portability. They are especially favored by patients who require frequent insulin administration, as they allow for more accurate dosing and a less intrusive experience compared to traditional syringes. Insulin pens are expected to continue dominating the market as advancements in pen technology, such as prefilled cartridges and adjustable dosage options, enhance patient satisfaction and treatment adherence. Syringes, while still widely used, are gradually being supplanted by pens due to their perceived discomfort and inconvenience. However, they remain an important segment of the market, particularly among patients with limited access to more modern devices. The “others” category includes insulin pumps and other advanced insulin delivery devices, which are growing in popularity, especially for patients seeking continuous insulin infusion and more precise glucose control.
By Indication:
The market is also segmented based on the indication for which human insulin is prescribed, including Type 1 diabetes, Type 2 diabetes, and gestational diabetes. Type 1 diabetes, an autoimmune condition that typically develops in childhood or early adulthood, is a significant segment of the market as it requires lifelong insulin therapy for blood sugar regulation. Type 2 diabetes, more common in adults and often associated with lifestyle factors, represents the largest segment due to its high prevalence in Turkey. Although Type 2 diabetes can sometimes be managed with oral medications, insulin therapy remains a critical component for many patients, especially those with advanced stages of the condition. Gestational diabetes, which occurs during pregnancy, is a smaller but growing segment as the prevalence of gestational diabetes rises. Treatment for gestational diabetes often includes insulin administration to manage blood sugar levels, providing a niche yet important market for human insulin.
Segments:
Based on Device:
Pens
Syringes
Others
Based on Indication:
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Based on Insulin:
Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others
Based on Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Based on the Geography:
Istanbul
Ankara
Izmir
Other
Regional Analysis
Istanbul
Istanbul, as the largest and most populous city in Turkey, dominates the human insulin market with the highest market share. It is home to a significant portion of the country’s diabetic population due to its dense urban environment, modern healthcare facilities, and large number of healthcare professionals. The market share for Istanbul accounts for approximately 40-45% of Turkey’s total human insulin market. The city’s extensive healthcare infrastructure, including state-of-the-art clinics and hospitals, ensures high availability and accessibility of insulin therapies. Additionally, Istanbul’s economic status contributes to higher levels of healthcare spending, enabling a larger proportion of the population to access the latest diabetes treatments and technologies. The increasing number of healthcare awareness campaigns in Istanbul also helps to boost early diabetes detection and treatment.
Ankara
Ankara, the capital city of Turkey, holds the second-largest market share for human insulin in the country, accounting for roughly 25-30%. As the administrative and political center, Ankara has significant investments in healthcare infrastructure and services. The city’s hospitals, medical institutions, and research centers are among the most advanced in Turkey. The growing urban population and higher rates of diabetes diagnosis and treatment in Ankara further drive the demand for insulin. Additionally, the presence of major universities and research centers in Ankara has contributed to advancements in medical research and the adoption of newer diabetes management technologies, further supporting the growth of the insulin market.
Izmir
Izmir, located on the western coast of Turkey, holds a market share of around 15-18%. As the third-largest city, Izmir benefits from its robust healthcare sector, which includes both public and private healthcare providers. The region has a relatively high number of diabetes patients, driven by both urban and rural populations, which necessitates consistent access to insulin. The demand for human insulin in Izmir is also supported by the city’s healthcare awareness initiatives and the growing adoption of diabetes management technologies, such as insulin pens and pumps. The increase in lifestyle-related diabetes cases in Izmir is expected to continue boosting the market for insulin therapies in the region.
Other regions
Other regions of Turkey, including smaller cities and rural areas, account for the remaining 10-15% of the human insulin market. Although these regions have a lower market share compared to the major cities, there is still a significant demand for insulin therapies driven by the growing prevalence of diabetes in these areas. In particular, rural areas are seeing improvements in healthcare access due to government programs aimed at extending medical services to underserved regions. The market in these areas is expected to grow steadily as healthcare infrastructure improves and awareness of diabetes management rises.
Key Player Analysis
Novo Nordisk A/S
MannKind Corporation
Pfizer
Wockhardt
Biocon
Lupin
Tonghua Dongbao Pharmaceutical Co
Eli Lilly and Company
Atabay Enterprises
Competitive Analysis
The Turkey human insulin market is highly competitive, with both multinational and local players contributing to the market’s dynamics. Leading players in the market include Novo Nordisk A/S, Eli Lilly and Company, Pfizer, Atabay Enterprises, Biocon, MannKind Corporation, Wockhardt, Lupin, and Tonghua Dongbao Pharmaceutical Co. These companies hold a significant share of the market due to their established presence, wide distribution networks, and extensive product portfolios. These global players focus on continuous innovation in insulin formulations and delivery systems, ensuring that they meet the evolving needs of diabetic patients. They leverage their financial strength and global supply chains to maintain a competitive edge, often introducing newer insulin options that provide improved efficacy and convenience. Local pharmaceutical companies, while facing intense competition from global giants, focus on offering affordable alternatives to human insulin. These companies play a critical role in expanding access to insulin, particularly in rural and underserved regions, by offering lower-cost insulin products. With a better understanding of the local market dynamics, including regulatory frameworks and patient preferences, these companies can quickly adapt and cater to the specific needs of Turkish consumers. As competition increases, both multinational and local companies are likely to focus on differentiation strategies through pricing, innovative delivery methods, and increasing accessibility to maintain and grow their market share.
Recent Developments
In April 2025, Novo Nordisk announced the discontinuation of Human Mixtard, India’s largest-selling human insulin brand, as part of a global strategy to prioritize newer, patented diabetes and weight loss therapies such as Ozempic and Wegovy. While vial forms of Mixtard, Actrapid, and Insulatard will remain available, pen devices (Penfills and FlexPens) are being phased out, which is expected to disrupt patient access and preference in India.
In April 2025, Pfizer discontinued the development of danuglipron, its once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, following a case of drug-induced liver injury and after reviewing clinical and regulatory feedback. This decision halts further clinical development for both obesity and diabetes indications.
In March 2025, Biocon Biologics entered a strategic collaboration with Civica, Inc. to expand access to Insulin Aspart in the United States. Biocon will supply the drug substance, which Civica will formulate and commercialize after completing development and clinical trials.
In December 2024, Lupin acquired the Huminsulin® portfolio in India from Eli Lilly and Company. The range includes Insulin Human (Huminsulin R, NPH, 50/50, and 30/70) and is indicated for type 1 and type 2 diabetes. Lupin had previously marketed these products under a distribution agreement, and the acquisition is aimed at strengthening its diabetes portfolio.
In November 2024, MannKind’s Afrezza® (insulin human) Inhalation Powder received approval from India’s CDSCO. MannKind expects to ship product to its partner Cipla by the end of 2025.
In October 2024, Wockhardt filed for approval of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). The product, developed indigenously, will be offered in cartridges, vials, and prefilled disposable pens. This expands Wockhardt’s diabetes biosimilars portfolio and addresses a market with limited competition.
Market Concentration & Characteristics
The market concentration of the Turkey human insulin sector is relatively high, with a few dominant multinational pharmaceutical companies holding a significant share of the market. These global players, due to their extensive research and development capabilities, strong distribution networks, and established brand recognition, lead the market. However, local manufacturers are also present, contributing to the overall competition by offering more affordable insulin products and targeting specific regional needs. The Turkish human insulin market is characterized by a combination of innovation in insulin formulations, such as faster-acting or longer-lasting insulin types, and the adoption of advanced delivery systems like insulin pens and pumps. Additionally, there is a strong focus on improving accessibility and affordability, especially in rural areas, where local companies often play a critical role. As the market evolves, companies are increasingly focusing on differentiation through pricing strategies, technological advancements, and tailored solutions to maintain a competitive edge.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
The research report offers an in-depth analysis based on Device,Indication, Insulin,Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
The demand for human insulin in Turkey will continue to grow due to the rising prevalence of diabetes, particularly among the aging population.
Technological advancements in insulin delivery systems, including insulin pumps and pens, will drive market growth as they improve patient convenience and treatment adherence.
Increased healthcare access and government initiatives will facilitate broader insulin distribution, particularly in underserved and rural regions.
The market will experience competition from biosimilars, offering more affordable alternatives to traditional human insulin.
A shift toward more personalized diabetes treatments is expected, leading to greater adoption of tailored insulin therapies.
As lifestyle-related diabetes cases increase, there will be a rising need for more accessible and affordable insulin products.
Regional disparities in insulin access will remain a challenge, though improvements in infrastructure are likely to help mitigate this gap.
Ongoing research and development efforts will lead to innovations in insulin formulations, enhancing efficacy and reducing side effects.
Growing awareness and education campaigns will contribute to early diagnosis and better management of diabetes, boosting insulin demand.
Strategic partnerships between pharmaceutical companies and healthcare providers will help expand the reach of human insulin products across Turkey.
CHAPTER NO. 1 : INTRODUCTION 19
1.1.1. Report Description 19 Purpose of the Report 19 USP & Key Offerings 19
1.1.2. Key Benefits for Stakeholders 19
1.1.3. Target Audience 20
1.1.4. Report Scope 20 CHAPTER NO. 2 : EXECUTIVE SUMMARY 21
2.1. Human Insulin Market Snapshot 21
2.1.1. Turkey Human Insulin Market, 2018 – 2032 (USD Million) 22 CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23
3.1. Russia-Ukraine and Israel-Palestine War Impacts 23 CHAPTER NO. 4 : HUMAN INSULIN MARKET – INDUSTRY ANALYSIS 24
4.1. Introduction 24
4.2. Market Drivers 25
4.2.1. Driving Factor 1 Analysis 25
4.2.2. Driving Factor 2 Analysis 26
4.3. Market Restraints 27
4.3.1. Restraining Factor Analysis 27
4.4. Market Opportunities 28
4.4.1. Market Opportunity Analysis 28
4.5. Porter’s Five Forces Analysis 29
4.6. Value Chain Analysis 30
4.7. Buying Criteria 31 CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32
5.1. Import Analysis by Turkey 32
5.1.1. Turkey Human Insulin Market Import Volume/Revenue, By Turkey, 2018 – 2023 32
5.2. Export Analysis by Turkey 33
5.2.1. Turkey Human Insulin Market Export Volume/Revenue, By Turkey, 2018 – 2023 33 CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34
6.1. Demand Analysis by Turkey 34
6.1.1. Turkey Human Insulin Market Demand Volume/Revenue, By Turkey, 2018 – 2023 34
6.2. Supply Analysis by Turkey 35
6.2.1. Turkey Human Insulin Market Supply Volume/Revenue, By Turkey, 2018 – 2023 35 CHAPTER NO. 7 : PRODUCTION ANALYSIS 36
7.1. Production Analysis by Turkey 36
7.1.1. Turkey Human Insulin Market Production Volume/Revenue, By Turkey, 2018 – 2023 36 CHAPTER NO. 8 : PRICE ANALYSIS 37
8.1. Price Analysis by Type 37
8.1.1. Turkey Human Insulin Market Price, By Type, 2018 – 2023 37
8.1.2. Turkey Type Market Price, By Type, 2018 – 2023 37 CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38
9.1. Key Raw Materials and Suppliers 38
9.2. Key Raw Materials Price Trend 38 CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39
10.1. Manufacturing Cost Analysis 39
10.2. Manufacturing Process 39 CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40
11.1. Company Market Share Analysis – 2023 40
11.1.1. Turkey Human Insulin Market: Company Market Share, by Volume, 2023 40
11.1.2. Turkey Human Insulin Market: Company Market Share, by Revenue, 2023 41
11.1.3. Turkey Human Insulin Market: Top 6 Company Market Share, by Revenue, 2023 41
11.1.4. Turkey Human Insulin Market: Top 3 Company Market Share, by Revenue, 2023 42
11.2. Turkey Human Insulin Market Company Volume Market Share, 2023 43
11.3. Turkey Human Insulin Market Company Revenue Market Share, 2023 44
11.4. Company Assessment Metrics, 2023 45
11.4.1. Stars 45
11.4.2. Emerging Leaders 45
11.4.3. Pervasive Players 45
11.4.4. Participants 45
11.5. Start-ups /SMEs Assessment Metrics, 2023 45
11.5.1. Progressive Companies 45
11.5.2. Responsive Companies 45
11.5.3. Dynamic Companies 45
11.5.4. Starting Blocks 45
11.6. Strategic Developments 46
11.6.1. Acquisitions & Mergers 46 New Product Launch 46 Turkey Expansion 46
11.7. Key Players Product Matrix 47 CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48
12.1. PESTEL 48
12.1.1. Political Factors 48
12.1.2. Economic Factors 48
12.1.3. Social Factors 48
12.1.4. Technological Factors 48
12.1.5. Environmental Factors 48
12.1.6. Legal Factors 48
12.2. Adjacent Market Analysis 48 CHAPTER NO. 13 : HUMAN INSULIN MARKET – BY TYPE SEGMENT ANALYSIS 49
13.1. Human Insulin Market Overview, by Type Segment 49
13.1.1. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50
13.1.2. Human Insulin Market Attractiveness Analysis, By Type 51
13.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 51
13.1.4. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52
13.2. Pens 53
13.3. Syringes 54
13.4. Others 55
13.5. Type 4 56
13.6. Type 5 57 CHAPTER NO. 14 : HUMAN INSULIN MARKET – BY APPLICATION SEGMENT ANALYSIS 58
14.1. Human Insulin Market Overview, by Application Segment 58
14.1.1. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59
14.1.2. Human Insulin Market Attractiveness Analysis, By Application 60
14.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 60
14.1.4. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61
14.2. Type 1 Diabetes 62
14.3. Type 2 Diabetes 63
14.4. Gestational Diabetes 64
14.5. Application 4 65
14.6. Application 5 66 CHAPTER NO. 15 : HUMAN INSULIN MARKET – BY END-USER SEGMENT ANALYSIS 67
15.1. Human Insulin Market Overview, by End-user Segment 67
15.1.1. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68
15.1.2. Human Insulin Market Attractiveness Analysis, By End-user 69
15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 69
15.1.4. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70
15.2. Rapid-acting insulin 71
15.3. Short-acting insulin 72
15.4. Intermediate-acting insulin 73
15.5. Others 74
15.6. End-user 5 75 CHAPTER NO. 16 : HUMAN INSULIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76
16.1. Human Insulin Market Overview, by Technology Segment 76
16.1.1. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77
16.1.2. Human Insulin Market Attractiveness Analysis, By Technology 78
16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78
16.1.4. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79
16.2. Technology 1 80
16.3. Technology 2 81
16.4. Technology 3 82 CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83
17.1. Human Insulin Market Overview, by Distribution Channel Segment 83
17.1.1. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84
17.1.2. Human Insulin Market Attractiveness Analysis, By Distribution Channel 85
17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85
17.1.4. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86
17.2. Hospital Pharmacies 87
17.3. Drug Stores and Retail Pharmacies 88
17.4. Online Providers 89
17.5. Distribution Channel 4 90
17.6. Distribution Channel 5 91 CHAPTER NO. 18 : HUMAN INSULIN MARKET – TURKEY ANALYSIS 92
18.1. Type 92
18.1.1. Turkey Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 92
18.2. Turkey Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 92
18.3. Application 93
18.3.1. Turkey Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 93
18.3.2. Turkey Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 93
18.4. End-user 94
18.4.1. Turkey Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 94
18.4.2. Turkey Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 94
18.5. Technology 95
18.5.1. Turkey Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 95
18.5.2. Turkey Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 95
18.6. Distribution Channel 96
18.6.1. Turkey Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96
18.6.2. Turkey Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96 CHAPTER NO. 19 : COMPANY PROFILES 97
19.1. Novo Nordisk A/S 97
19.1.1. Company Overview 97
19.1.2. Product Portfolio 97
19.1.3. Swot Analysis 97
19.1.4. Business Strategy 98
19.1.5. Financial Overview 98
19.1.6. MannKind Corporation 99
19.1.7. Pfizer 99
19.1.8. Wockhardt 99
19.1.9. Biocon 99
19.1.10. Lupin 99
19.1.11. Tonghua Dongbao Pharmaceutical Co 99
19.1.12. Eli Lilly and Company 99
19.1.13. Atabay enterprises 99
19.1.14. Company 10 99
19.1.15. Company 11 99
19.1.16. Company 12 99
19.1.17. Company 13 99
19.1.18. Company 14 99 CHAPTER NO. 20 : RESEARCH METHODOLOGY 100
20.1. Research Methodology 100
20.1.1. Phase I – Secondary Research 101
20.1.2. Phase II – Data Modeling 101 Company Share Analysis Model 102 Revenue Based Modeling 102
20.1.3. Phase III – Primary Research 103
20.1.4. Research Limitations 104 Assumptions 104
List of Figures
FIG NO. 1. Turkey Human Insulin Market Revenue, 2018 – 2032 (USD Million) 22
FIG NO. 2. Porter’s Five Forces Analysis for Turkey Human Insulin Market 29
FIG NO. 3. Value Chain Analysis for Turkey Human Insulin Market 30
FIG NO. 4. Turkey Human Insulin Market Import Volume/Revenue, By Turkey, 2018 – 2023 32
FIG NO. 5. Turkey Human Insulin Market Export Volume/Revenue, By Turkey, 2018 – 2023 33
FIG NO. 6. Turkey Human Insulin Market Demand Volume/Revenue, By Turkey, 2018 – 2023 34
FIG NO. 7. Turkey Human Insulin Market Supply Volume/Revenue, By Turkey, 2018 – 2023 35
FIG NO. 8. Turkey Human Insulin Market Production Volume/Revenue, By Turkey, 2018 – 2023 36
FIG NO. 9. Turkey Human Insulin Market Price, By Type, 2018 – 2023 37
FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38
FIG NO. 11. Manufacturing Cost Analysis 39
FIG NO. 12. Manufacturing Process 39
FIG NO. 13. Company Share Analysis, 2023 40
FIG NO. 14. Company Share Analysis, 2023 41
FIG NO. 15. Company Share Analysis, 2023 41
FIG NO. 16. Company Share Analysis, 2023 42
FIG NO. 17. Human Insulin Market – Company Volume Market Share, 2023 43
FIG NO. 18. Human Insulin Market – Company Revenue Market Share, 2023 44
FIG NO. 19. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50
FIG NO. 20. Market Attractiveness Analysis, By Type 51
FIG NO. 21. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 51
FIG NO. 22. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52
FIG NO. 23. Turkey Human Insulin Market for Pens, Revenue (USD Million) 2018 – 2032 53
FIG NO. 24. Turkey Human Insulin Market for Syringes, Revenue (USD Million) 2018 – 2032 54
FIG NO. 25. Turkey Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 55
FIG NO. 26. Turkey Human Insulin Market for Type 4, Revenue (USD Million) 2018 – 2032 56
FIG NO. 27. Turkey Human Insulin Market for Type 5, Revenue (USD Million) 2018 – 2032 57
FIG NO. 28. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59
FIG NO. 29. Market Attractiveness Analysis, By Application 60
FIG NO. 30. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 60
FIG NO. 31. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61
FIG NO. 32. Turkey Human Insulin Market for Type 1 Diabetes, Revenue (USD Million) 2018 – 2032 62
FIG NO. 33. Turkey Human Insulin Market for Type 2 Diabetes, Revenue (USD Million) 2018 – 2032 63
FIG NO. 34. Turkey Human Insulin Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 64
FIG NO. 35. Turkey Human Insulin Market for Application 4, Revenue (USD Million) 2018 – 2032 65
FIG NO. 36. Turkey Human Insulin Market for Application 5, Revenue (USD Million) 2018 – 2032 66
FIG NO. 37. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68
FIG NO. 38. Market Attractiveness Analysis, By End-user 69
FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69
FIG NO. 40. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70
FIG NO. 41. Turkey Human Insulin Market for Rapid-acting insulin, Revenue (USD Million) 2018 – 2032 71
FIG NO. 42. Turkey Human Insulin Market for Short-acting insulin, Revenue (USD Million) 2018 – 2032 72
FIG NO. 43. Turkey Human Insulin Market for Intermediate-acting insulin, Revenue (USD Million) 2018 – 2032 73
FIG NO. 44. Turkey Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 74
FIG NO. 45. Turkey Human Insulin Market for End-user 5, Revenue (USD Million) 2018 – 2032 75
FIG NO. 46. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77
FIG NO. 47. Market Attractiveness Analysis, By Technology 78
FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78
FIG NO. 49. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79
FIG NO. 50. Turkey Human Insulin Market for Technology 1, Revenue (USD Million) 2018 – 2032 80
FIG NO. 51. Turkey Human Insulin Market for Technology 2, Revenue (USD Million) 2018 – 2032 81
FIG NO. 52. Turkey Human Insulin Market for Technology 3, Revenue (USD Million) 2018 – 2032 82
FIG NO. 53. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84
FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85
FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85
FIG NO. 56. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86
FIG NO. 57. Turkey Human Insulin Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 87
FIG NO. 58. Turkey Human Insulin Market for Drug Stores and Retail Pharmacies, Revenue (USD Million) 2018 – 2032 88
FIG NO. 59. Turkey Human Insulin Market for Online Providers, Revenue (USD Million) 2018 – 2032 89
FIG NO. 60. Turkey Human Insulin Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90
FIG NO. 61. Turkey Human Insulin Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91
FIG NO. 62. Research Methodology – Detailed View 100
FIG NO. 63. Research Methodology 101
List of Tables
TABLE NO. 1. : Turkey Human Insulin Market: Snapshot 18
TABLE NO. 2. : Drivers for the Human Insulin Market: Impact Analysis 22
TABLE NO. 3. : Restraints for the Human Insulin Market: Impact Analysis 24
TABLE NO. 4. : Turkey Human Insulin Market Revenue, By Type, 2018 – 2023 34
TABLE NO. 5. : Key Raw Materials & Suppliers 35
TABLE NO. 6. : Turkey Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 89
TABLE NO. 7. : Turkey Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 89
TABLE NO. 8. : Turkey Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 90
TABLE NO. 9. : Turkey Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 90
TABLE NO. 10. : Turkey Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 91
TABLE NO. 11. : Turkey Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 91
TABLE NO. 12. : Turkey Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 92
TABLE NO. 13. : Turkey Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 92
TABLE NO. 14. : Turkey Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93
TABLE NO. 15. : Turkey Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93
Frequently Asked Questions:
What is the current size of the Turkey Human Insulin?
The Turkey Human Insulin market was valued at USD 135.59 million in 2023 and is projected to reach USD 169.44 million by 2032, growing at a CAGR of 2.48%.
What factors are driving the growth of the Turkey Human Insulin?
Growth is driven by rising diabetes prevalence, healthcare reforms, technological advancements in insulin delivery, and increasing awareness of diabetes management.
What are the key segments within the Turkey Human Insulin?
Key segments include Device (Pens, Syringes, Others), Indication (Type 1, Type 2, Gestational Diabetes), Insulin Type, Distribution Channel, and Geography.
What are some challenges faced by the Turkey Human Insulin?
Challenges include high dependency on imports, pricing volatility, competition from biosimilars, and regional disparities in insulin access.
Who are the major players in the Turkey Human Insulin?
Major players include Novo Nordisk A/S, Eli Lilly and Company, Pfizer, Atabay Enterprises, Biocon, and MannKind Corporation.
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing.
$2699
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis and multi-location access, making it an excellent choice for organizations with distributed workforce.
$3699
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc.’s research team. It is highly recommended for organizations seeking to execute short, customized research projects related to the scope of the purchased report.
I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.
